A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of SPI-8811 Oral Solution in Patients With Non-erosive Reflux Disease (NERD) Refractory to Proton Pump Inhibitors
Phase 2
- Conditions
- on-erosive Reflux Disease
- Registration Number
- JPRN-jRCT2080222711
- Lead Sponsor
- Sucampo Pharma, LLC.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patient has non-erosive reflux disease and insufficient response to the standard dose of a PPI.
Patient who has no mucosal change by upper gastrointestinal tract endoscopy on the day before the study treatment.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method